NEW YORK, May 14 – Aptus Genomics added $6.2 million to its coffers in its latest round of financing, the Rockville, Maryland-based company announced Monday.
The funding came from Emerging Technology Partners, The Grosvenor Funds, and VitalBio.
Aptus develops technology platforms to discover and analyze the function of selected families of human genes. The company, founded in June 2000, has stated it is initially concentrating its efforts on cell surface receptors. The latest round of funding will be used in R&D, staffing and general expenses, according to the company.
"Aptus’ focus on research enablement through gene discovery, qualification, and utilization will allow biotech and pharmaceutical companies, as well as Aptus’ own researchers, to accelerate drug discovery," Wei-Wu He of Emerging Technology Partners said in a statement. He is also Aptus’ Chairman of the Board.